96 related articles for article (PubMed ID: 27320318)
1. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
2. Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.
Ma C; Wang X; Dai JY; Turman C; Kraft P; Stopsack KH; Loda M; Pettersson A; Mucci LA; Stanford JL; Penney KL
Cancer Epidemiol Biomarkers Prev; 2023 Oct; 32(10):1436-1443. PubMed ID: 37555839
[TBL] [Abstract][Full Text] [Related]
3. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
Graff RE; Pettersson A; Lis RT; DuPre N; Jordahl KM; Nuttall E; Rider JR; Fiorentino M; Sesso HD; Kenfield SA; Loda M; Giovannucci EL; Rosner B; Nguyen PL; Sweeney CJ; Mucci LA;
Prostate; 2015 Jun; 75(9):897-906. PubMed ID: 25728532
[TBL] [Abstract][Full Text] [Related]
4.
Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
[No Abstract] [Full Text] [Related]
5. Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration.
Rao SR; Alham NK; Upton E; McIntyre S; Bryant RJ; Cerundolo L; Bowes E; Jones S; Browne M; Mills I; Lamb A; Tomlinson I; Wedge D; Browning L; Sirinukunwattana K; Palles C; Hamdy FC; Rittscher J; Verrill C
J Mol Diagn; 2020 May; 22(5):652-669. PubMed ID: 32229180
[TBL] [Abstract][Full Text] [Related]
6. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis.
Prasad RR; Mishra N; Kant R; Fox JT; Shoemaker RH; Agarwal C; Raina K; Agarwal R
Mol Carcinog; 2024 Jun; 63(6):1188-1204. PubMed ID: 38506376
[TBL] [Abstract][Full Text] [Related]
7. A cross-sectional study of ERG expression and the relationship with clinicopathological features of Prostate cancer in Southwestern Uganda.
Mitala Y; Ssenkumba B; Birungi A; Kiconco R; Mutakooha MM; Atwine R
Diagn Pathol; 2024 May; 19(1):67. PubMed ID: 38730435
[TBL] [Abstract][Full Text] [Related]
8. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
Yin L; Rao P; Elson P; Wang J; Ittmann M; Heston WD
PLoS One; 2011; 6(6):e21319. PubMed ID: 21731703
[TBL] [Abstract][Full Text] [Related]
9. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.
Ahearn TU; Peisch S; Pettersson A; Ebot EM; Zhou CK; Graff RE; Sinnott JA; Fazli L; Judson GL; Bismar TA; Rider JR; Gerke T; Chan JM; Fiorentino M; Flavin R; Sesso HD; Finn S; Giovannucci EL; Gleave M; Loda M; Li Z; Pollak M; Mucci LA;
Carcinogenesis; 2018 Dec; 39(12):1431-1437. PubMed ID: 30165429
[TBL] [Abstract][Full Text] [Related]
10. Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images.
Omar M; Xu Z; Rand SB; Alexanderani MK; Salles DC; Valencia I; Schaeffer EM; Robinson BD; Lotan TL; Loda M; Marchionni L
Mol Cancer Res; 2024 Apr; 22(4):347-359. PubMed ID: 38284821
[TBL] [Abstract][Full Text] [Related]
11. No differences in miRNA expression in the stroma of ERG+ and ERG- prostate cancers.
Wątor G; Kołton-Wróż M; Wołkow P; Bełch Ł; Chłosta P; Szpor J; Klimkowska A; Nejman K; Józkowicz A; Piechota-Polańczyk A; Okoń K
Pol J Pathol; 2023; 74(4):265-270. PubMed ID: 38477088
[TBL] [Abstract][Full Text] [Related]
12. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells.
Wilson S; Greer B; Hooper J; Zijlstra A; Walker B; Quigley J; Hawthorne S
Biochem J; 2005 Jun; 388(Pt 3):967-72. PubMed ID: 15537383
[TBL] [Abstract][Full Text] [Related]
13. Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer.
Woo J; Santasusagna S; Banks J; Pastor-Lopez S; Yadav K; Carceles-Cordon M; Dominguez-Andres A; Den RB; Languino LR; Pippa R; Lallas CD; Lu-Yao G; Kelly WK; Knudsen KE; Rodriguez-Bravo V; Tewari AK; Prats JM; Leiby BE; Gomella LG; Domingo-Domenech J
J Urol; 2020 Oct; 204(4):691-700. PubMed ID: 32250729
[TBL] [Abstract][Full Text] [Related]
14. RNA-seq Based Transcription Characterization of Fusion Breakpoints as a Potential Estimator for Its Oncogenic Potential.
Gu JL; Chukhman M; Lu Y; Liu C; Liu SY; Lu H
Biomed Res Int; 2017; 2017():9829175. PubMed ID: 29181411
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of genomic integrity after DNA double strand breaks in the human prostate and seminal vesicle epithelium: the best and the worst.
Jäämaa S; Laiho M
Mol Oncol; 2012 Oct; 6(5):473-83. PubMed ID: 22762987
[TBL] [Abstract][Full Text] [Related]
16. Detection of fusion gene transcripts in the blood samples of prostate cancer patients.
Yu YP; Liu S; Nelson J; Luo JH
Sci Rep; 2021 Aug; 11(1):16995. PubMed ID: 34417538
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.
Krstanoski Z; Vokac NK; Zagorac A; Pospihalj B; Munda M; Dzeroski S; Golouh R
BMC Urol; 2016 Jul; 16(1):35. PubMed ID: 27377958
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and clinical application of
Kong DP; Chen R; Zhang CL; Zhang W; Xiao GA; Wang FB; Ta N; Gao X; Sun YH
Asian J Androl; 2020; 22(2):200-207. PubMed ID: 31210145
[TBL] [Abstract][Full Text] [Related]
19. Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.
Pakula H; Linn DE; Schmidt DR; Van Gorsel M; Vander Heiden MG; Li Z
Methods Mol Biol; 2018; 1786():131-151. PubMed ID: 29786791
[TBL] [Abstract][Full Text] [Related]
20. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
